WO2011112554A1 - Nouvelles approches thérapeutiques pour le syndrome de birt-hogg-dube (bhd) - Google Patents

Nouvelles approches thérapeutiques pour le syndrome de birt-hogg-dube (bhd) Download PDF

Info

Publication number
WO2011112554A1
WO2011112554A1 PCT/US2011/027507 US2011027507W WO2011112554A1 WO 2011112554 A1 WO2011112554 A1 WO 2011112554A1 US 2011027507 W US2011027507 W US 2011027507W WO 2011112554 A1 WO2011112554 A1 WO 2011112554A1
Authority
WO
WIPO (PCT)
Prior art keywords
bhd
cells
cell
expression
bim
Prior art date
Application number
PCT/US2011/027507
Other languages
English (en)
Inventor
Timothy Cash
Celeste M. Simon
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2011112554A1 publication Critical patent/WO2011112554A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Definitions

  • Birt-Hogg-Dube (BHD) syndrome is a rare, inherited cancer susceptibility disease characterized by benign hair follicle tumors and lung cysts in a majority of patients, and renal cell carcinoma (RCC) in approximately one-third of diagnosed BHD cases (Schmidt et al., 2005, Am J Hum Genet 76(6): 1023-1033).
  • RRC renal cell carcinoma
  • BHD syndrome results from !oss-of-function mutations in the BHD gene.
  • BHD is also inactivated in a significant fraction of patients with sporadic renal cancers and idiopathic cystic lung disease, and little is known about its mode of action.
  • BHD protein encoded by BHD
  • folliculin the cellular and molecular mechanisms of the protein encoded by BHD, also called folliculin. Dissecting BHD's molecular functions is particularly challenging since the BHD gene product bears no sequence or functional homology to any known protein. Studies in S.
  • pombe have suggested a role for the putative yeast BHD ortholog in amino acid homeostasis, while siRNA-mediated knockdown of Drosop ila BHD in the fly has implicated it in male germline stem cell maintenance through Stat and/or BMP signaling (Singh et al, 2006, Oncogene 25(44):5933-5941 ; van S timesenhorst et al , 2007, J Biol Chem 282(34):24583- 24590).
  • the invention includes a method of treating a BHD-based tumor in a mammal.
  • the method comprises administering to a mammal an effective amount of a therapeutic agent that promotes or induces TGF- ⁇ dependent apoptosis in the BHD-based tumor.
  • the mammal is a human.
  • the therapeutic agent is a BH3-only molecule.
  • the BH3-only molecule is a protein selected from the group consisting of BID, BIM, BAD and NOXA,
  • the BH3-only molecule is a mimetic.
  • the BH3-only mimetic is ABT-737.
  • the therapeutic agent is an HDAC inhibitor.
  • the HDAC inhibitor is Trichostatin.
  • the HDAC inhibitor is Vorinostat.
  • the therapeutic agent is an autophagy inhibitor.
  • the autophagy inhibitor is chloroquine.
  • the autophagy inhibitor is 3-methyi-adenine (3- MA).
  • the therapeutic agent is an expression vector encoding BHD.
  • the therapeutic agent is an expression vector encoding BIM.
  • the invention also includes a method for promoting or inducing TGF- ⁇ dependent apoptosis in a BHD-based tumor cell of a mammal.
  • the method comprises contacting the cell with an effective amount of a therapeutic agent.
  • the mammal is a human
  • the therapeutic agent is selected from the group consisting of a BH3-onfy molecule, an HDAC inhibitor and an autophagy inhibitor.
  • the therapeutic agent is an expression vector encoding BHD.
  • the therapeutic agent is an expression vector encoding BIM.
  • the invention further includes a composition for promoting or inducing TGF- ⁇ dependent apoptosis in a BHD-based tumor cell of a mammal.
  • the composition comprises a BH3-oniy molecule.
  • the invention also includes a composition for promoting or inducing TGF- ⁇ dependent apoptosis in a BHD-based tumor cell of a mammal.
  • the composition comprises an HDAC inhibitor,
  • the invention further includes a composition for promoting or inducing TGF- ⁇ dependent apoptosis in a BHD-based tumor cell of a mammal.
  • the composition comprises an autophagy inhibitor.
  • the invention also includes a composition for promoting or inducing TGF- ⁇ dependent apoptosis in a BHD-based tumor celi of a mammal.
  • the composition comprises an expression vector encoding BHD.
  • the invention further includes a composition for promoting or inducing TGF- ⁇ dependent apoptosis in a BHD-based tumor cell of a mammal.
  • the composition comprises an expression vector encoding BIM.
  • Figure 1 is a series of charts and images demonstrating that Bhcf" /m embryos are early embryonic lethal.
  • Figure 1(A) is a schematic depicting the integration site of Bay Genomics PGTX2 gene trap vector in murine Bhd intron 8, the location of probe and restriction sites for Southern blot genotyping, and location of primers (P I , P2, and P3) for PCR-based genotyping.
  • Figure 1 (B) depicts a Southern blot of PvuII- digested genomic DNA.
  • Figure 1 (C) depicts PCR-based genotypes of B c /+ or Bhc /m ES cells to discriminate wild-type (WT) from mutant (MUT) alleles, where m specifically designates the gene-trapped mutant Bhd allele from Bay Genomics.
  • Figure 1 (D) depicts relative Bhd mRNA levels in Bhd" /+ vs. Bh /m ES cells assayed by qRT-PCR, using primers spanning exons just downstream of the trap cassette (exons 9- 10) or across the terminal exons of the Bhd gene (exons 12-13), ruling out the presence of aberrant transcripts generated from cryptic transcriptional start sites downstream of the trap cassette.
  • Figure 1(E) depicts X-Gal staining, showing Bh ⁇ m ES ceils express the Bhd-ftgalactosidase fusion product.
  • Figure 1 (F) is a table of progeny obtained from Bhd m intercrosses, showing no Bhd' ' embryos could be recovered after e6,5.
  • Tn Figure 1 (F), (*) indicates probable genotypes of embryos based on normal vs. abnormal phenotypic appearance at e6.5
  • Figure 1(G) depicts 20x images of H&E stained cross-sections of paraffin embedded e6.5 embryos from Bhd*'" 1 intercrosses.
  • Figure 1 (G) (a) exemplifies normal morphology while (b) and (c) demonstrate gross abnormal ities, probable Bhd"'" genotypes.
  • Figure 2 is a series of charts and images characterizing the German Gene Trap 2?Af/alie!e.
  • Figure 2(A) is a schematic depicting the integration site of FlipRosageo trap vector in intron ⁇ of the murine Bhd gene, as well as the location of probe and restriction digest sites for Southern blot genotyping, as well as primer positions (PI , P2, P3) for PCR-based genotyping.
  • Figure 2(B) depicts a Southern blot
  • Figure 2(C) depicts PCR-based genotyping, of Bhc ' + vs Bhd*' " ES cells to discriminate wild-type (WT) from mutant (MUT) alleles.
  • FIG. 1 denotes the gene-trapped mutant Bhd allele obtained from the German Gene Trap Consortium throughout the manuscript.
  • Figure 2(D) depicts a qRT-PCR analysis of Bhd expression levels using primers just downstream (exons 1-2) or far downstream (exons 9- 10, 12- 13) from the trap integration site.
  • Figure 2(E) depicts X-gal staining demonstrating Bhcf ' ES cells express ⁇ -galactosidase from the trap cassette.
  • Figure 3 is a series of charts and images demonstrating that Bh ' ' ES cells do not have a proliferative or growth advantage, but are resistant to apoptosis.
  • Figure 3(A) depicts PCR genotypes verifying loss of wild-type Bhd allele in three independent ES clones, designated as 1 , 2 and 3, after step-up selection.
  • Figure 3(B) depicts a Western blot demonstrating loss of BHD protein expression in three independent Bhd' ES clones.
  • Figure 3(C) depicts a growth curve showing Bhd " ' ' ES cells proliferate similar to Bhc /+ and Bhd ' ' counterparts, but have increased saturation density.
  • Figure 3(E) depicts Bhd' ' ES cells that are significantly resistant to apoptosis, as shown by a brightfield image of Bh ' + and Bhd' ' ES cells starved of amino acids for one day.
  • Figure 3(F) depicts a representative FACs plot showing Bhd' ' ES cells have significantly less sub-G s DNA content following one day of amino acid starvation.
  • Figure 3(G) depicts a FACs analysis of cells containing sub-G[ DNA content after one day serum, glucose and amino acid (AA) deprivation compared to Bhc ' + and Bhct' ' cells, but not by TNF treatment (* p ⁇ .0000345).
  • Figure 3(H) depicts a Western blot of caspase and parp cleavage with and without amino acid starvation in Bhcf' + and Bhd' ' ES cells.
  • all bar graphs represent averages of three independent experiments with error bars showing standard error of the mean (SEM).
  • Figure 4 is a series of images demonstrating that Bhd' ' ES cells maintain characteristics of pluripotency in culture.
  • Figure 4(A) depicts a Western blot showing three independent Bhd' ' ES clones maintain expression of pluripotency factors Oct-4, Nanog and Sox2.
  • Figure 4(B) depicts a Western blot showing p-STAT3 (Y705) levels are unaffected even when cultured in non-saturating concentrations of LIF.
  • Figure 4(C) depicts stain positive for alkaline phosphatase, demonstrating observed effects are not due to precocious differentiation of Bhd' ' ES cells in culture.
  • Figure 5 is a series of charts and images demonstrating that death resistance of Bhd' ' cells is not due to increased intracellular amino acid levels but results from decreased Bim protein levels.
  • Figure 5(A) depicts intracellular amino acid levels normalized to total protein in Bh( ' + vs. Bhd' ' ES cells as assessed by HPLC. The data in Figure 5A represents the average of three independent experiments and error bars reflect standard deviation.
  • Figure 5(B) depicts a Western blot showing Bhd' ⁇ ES cells have decreased levels of several BH3-only proteins, most notably Bim.
  • Figure 5(C) depicts the quantification of sub-Gi populations by flow cytometry, where restoration of Bhd and BudiEL expression, or treatment with ABT-737 (ABT), chloroquine (CQ) or 3-methyl-adenine (3MA) rescues the death resistance phenotype of Bhd' ' ES cells in response to two-day amino acid-starvation, compared to untreated or vector-only ⁇ MSCV) infected controls,
  • ABT-737 ABT
  • CQ chloroquine
  • 3MA 3-methyl-adenine
  • Figure 5(D) depicts 20X images of paraffin-embedded sections of solid renal tumors (labeled T) from Bhct'"' mice 18-21 months in age (a-c), or a human patient exhibiting loss of Bim expression, compared to normal adjacent tissue (labeled N).
  • (a) and (b) are hybrid clear ce!l-oncocytic lesions
  • (c) is a solid papillary projection from a cyst
  • (d) is a human chromophobe CC.
  • Figure 6 comprising Figures 6A and 6B, demonstrate that Bhd"'"' ES cells also exhibit loss of Bim expression.
  • Figure 6(A) depicts PCR genotyping of Bhd ⁇ ' + , parental Bhct'" 1 (P) ES cells, two independent Bhct'"' clones (1 and 2) that underwent step-up selection without homozygosing the /// allele, and three independent Bhd" "' clones that homozygosed the Bhd” allele after step-up selection (denoted as 1 , 2 and 3).
  • Figure 6(B) is a Western blot depicting loss of BHD protein in Bhd' l m clones as well as loss of Bim protein expression. A non-specific band (N.S.) is shown for a loading control.
  • Figure 7 is a series of charts and images demonstrating that Bim is transcriptionally downregulated in Bhd A cells, but is not due to hyperactivation of mTORCl, mTORC2 or ER hyperactivation.
  • Figure 7(B) depicts a Western blot showing that mTORC l (indicated by p-S6Kl (T389) and ⁇ -4 ⁇ - ⁇ 1 (T70)), mTORC2 (indicated by p-Akt (S473) p-FoxO (FoxOl (Thr24)/Fox03a (Thr32)/Fox04 (Thr28)), ERK (indicated by p-MEK (S217/271), p-ERK (T202/Y204), and p-p90RSK (T359/S363)) signaling pathways are hyperactivated in Bhd BS cells.
  • mTORC l indicated by p-S6Kl (T389) and ⁇ -4 ⁇ - ⁇ 1 (T70)
  • mTORC2 indicated by p-Akt (S473)
  • p-FoxO FroxOl (Thr24)/Fox03a (Thr32)/Fox
  • Figure 7(C) depicts inhibition of hyperactivated mTORC2 by 5 ⁇ LY294002 (LY) or ERK by 10 ⁇ PD98059 (PD) or a combination of both, or inhibition of mTORCl by 20 nM rapamycin (rapa) for 24 hours, does not restore Bim protein expression levels in Bhd ceils by Western blot.
  • Drug efficacy is shown by decreased p-FOXO levels with LY treatment and decreased p-ERK levels with PD treatment in Bhd cells.
  • Decreased mobility shifts in S6K demonstrate effectiveness of both LY and rapa treatments. Doses were chosen based on their ability to bring activation levels of signaling components in Bhd cells to those seen in Bh(t + cells.
  • Figure 7(D) depicts Bhd A ES cells pre-treated for six hours with the same of panel inhibitors as 7(C), then starved of amino acids for two days with inhibitors being re-added after one day of starvation to maintain concentrations. Death was assessed by quantification of sub-Gi populations by flow cytometry (upper, * p ⁇ .0345) and caspase and parp cleavage by Western blot (lower). In Figure 7, all bar graphs represent averages of three independent experiments with error bars reflecting SEM.
  • Figure 8 comprising Figures 8A and 8B, demonstrate that loss of BHD does not affect 5/flj-specific miRNAs or Bim proteoyltic degradation.
  • Figure 8(A) depicts a Western blot showing that Bhd ES cells treated with 10 ⁇ MG-132 for 4 hours does not restore Bim protein levels, though iibquinited forms of HTF- l a accumulate. A non-specific band (N.S.) is shown as a loading control.
  • Figure 8(B) depicts Bhd A ES cells having similar levels of mir- 19 and mir-92 compared to Bh /+ and Bhcf counterparts as shown by Northern blot, with tryosyl-tRNA used a loading control.
  • Figure 9 is a series of images demonstrating that loss of BHD results in decreased amino-acid-sensitive eIF2ct phosphorylation but this does not account for Bim loss.
  • Figure 9(A) depicts a Western biot showing basal p-eIF2 (S51) levels are lower in Bhd A ES cells.
  • Figure 9(B) though elF2 phosphorylation in response to amino acid (AA) deprivation over a time course is attenuated in Bhd A ES cells, ATF4 and Chop accumulation is only slightly attenuated by examining nuclear extracts.
  • Figure 10 comprising Figures 10A-10G, is a series of charts and images
  • Figure 10(B) depicts qRT-PCR analysis showing canonical TGF target genes Lefty I, PAI-l, Co! 2 and Pi/x2 are significantly downregulated in multiple Bhd A ES cell clones (* p ⁇ .00829).
  • Figure 10(C) depicts X-gal stained 7x image of whole mount (a) or 20x image of sectioned (b) yolk sac taken from a e l 0.5 Bhc /m embryo exhibiting high Bhd expression in visceral endoderm of the yolk sac.
  • Figure 10(D) depicts a 20X image of day 12 EBs. Bhc /+ EBs form expanded cystic structures reminiscent of yolk sacs, while Bhd EBs fail to do so.
  • Figure 10(E) depicts a qRT-PCR analysis on RNA from embryoid bodies, showing B d ⁇ /+ EBS significantly fail to express maximal levels of mature yolk sac markers a-feto-protein (AFP) and trithioredoxin (TTR).
  • AFP a-feto-protein
  • TTR trithioredoxin
  • Data represents the average of three independent experiements with error bars showing standard deviation.
  • Figure 10(G) depicts a qRT-PCR analysis of Gatci-1 and CD34 mRNA expression in day 10 EBs in methylcelhilose cultures, which is significantly reduced in Bhd EBs ( ⁇ 4.49 x 10 "6 ).
  • Figure 1 1 comprising Figures 1 1 A and 1 I B, demonstrate that Bhd ' ES ceils have characteristics similar to TGFP-sign ling component mutants.
  • Figure 1 1(A) depicts qRT- PCR analysis of additional canonical transcriptional targets of TGF family ligands, showing that Lefly'2, SnoN and pi 5 are also downregulated in Bhd' ' ES ceils.
  • Figure 1 1 (B) is a representative image of benzediene-stained day 10 EB cultures grown in methylcelluiose, showing Bhd' ' ES cells generate no hemoglobinized colonies.
  • Figure 12 depicts a series of Graphs showing mRNA levels of Brachywy T, FGF-5 and HNF4 in Bhd v/ ⁇ and Bhd' ' EBs grown in suspension over a timecourse of 9 days, as measured by qRT-PCR.
  • Brachywy T a mesodermal marker is robustly induced in Bhd' ' EBs, though in a delayed fashion while overall induction of ectodermal marker Fgf-5 and early induction of endodermal marker Hnf4 occur normally.
  • Figure 12 demonstrates that Bhd' ' EBs induce mesodermal, ectodermal and early endodermal markers normally.
  • Figure 13 comprising Figures 13A-13F, is a series of charts and images
  • Figure 13(A) depicts a Western blot of nuclear abstracts showing basal or ( Figure 13(B)) induced levels after 30 minutes of 10 ng/mL activin stimulation of nuclear phospho- smad2, Smad2 and Smad4 accumulation is unaffected in Bhd' ' S cells.
  • the non-specific ( .S.) band is shown as a loading control
  • Figure 13(C) depicts qRT-PCR using primers located in the Lefty 1 promoter on genomic DNA immunoprecipitated with acetyl-histone H3 antibody from ES cells stimulated with activin for 1 hour following 24 hour culture in N2B27.
  • Figure 13(D) depicts a Western blot showing total levels of acetyl-H3 are unaffected in Bh( ' + vs. Bhd' ' cells with and without activin treatment.
  • Figure 13(E) shows treatment of Bhd' ' cells with trichostatin A (TSA) restores mRNA levels of PAl-1, pi 5 and Bim as depicted by qRT-PCR analysis of mRNA expression levels (* p ⁇ 0.0362).
  • TSA trichostatin A
  • Figure 14 comprising Figures 14 A and 14B, illustrates the model that loss of BHD leads to increased FfDAC-dependent repression of Smad-specific promoters.
  • Figure 14(A) depicts that in the presence of BHD, Smad-dependent transcription is active, allowing transcription of anti-apoptotic genes like Bim and anti-proliferative genes like pi 5 to promote tumor suppression.
  • Figure 14(B) when BHD is lost, Smad- dependent transcription is repressed and apoptotic and anti-proliferative responses are lost, leading to tumor formation.
  • the present invention encompasses compositions and methods for treating BHD- based tumors, as well as sporadic cases of cystic lung disease and renal ceil carcinoma, by correcting a defective apoptotic function that correlates with the absence of BHD, paiticulary the failure to undergo apoptosis as a result of misregulated TGFp-mediated chromatin modifications at target gene promoters.
  • the present invention is based on the discovery that BHD-deficient cells exhibited defects in cell-intrinsic apoptosis that correlated with reduced expression of the BH3-only protein Bim.
  • the present invention is also based on the discovery that Bim protein deficiency in Bhd 1' cells is not a consequence of elevated mTOR or ERK activity, but results instead from reduced Bim transcription associated with altered TGF-p-mediated chromatin modifications.
  • the compositions and methods of the invention are contemplated for use in a mammal, preferably, a human,
  • an element means one element or more than one element.
  • Allogeneic refers to a graft derived from a different animal of the same species.
  • Alloantigen is an antigen that differs from an antigen expressed by the recipient
  • antibody refers to an immunoglobulin molecule, which is able to specifically bind to a specific epitope on an antigen.
  • Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoactive portions of intact immunoglobulins.
  • Antibodies are typically tetramers of immunoglobulin molecules.
  • the antibodies in the present invention may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and 11 027507
  • F(ab)2 as well as single chain antibodies and humanized antibodies (Harlow et al., 1988; Houston et al., 1988; Bird et al., 1988).
  • antigen or "Ag” as used herein is defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific ininiimologically-competent cells, or both.
  • antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an "antigen" as that term is used herein.
  • an antigen need not be encoded solely by a full length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to elicit the desired immune response. Moreover, a skilled artisan will understand that an antigen need not be encoded by a "gene” at all. It is readily apparent that an antigen can be generated synthesized or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.
  • Antisense refers particularly to the nucleic acid sequence of the non-coding strand of a double stranded DNA molecule encoding a polypeptide, or to a sequence which is substantially homologous to the non-coding strand.
  • an antisense sequence is complementary to the sequence of a double stranded DNA molecule encoding a polypeptide, it is not necessary that the antisense sequence be complementary solely to the coding portion of the coding strand of the DNA molecule.
  • the antisense sequence may be complementary to regulatory sequences specified on the coding strand of a DNA molecule encoding a polypeptide, which regulatory sequences control expression of the coding sequences.
  • autologous is meant to refer to any material derived from the same individual to which it is later to be re-introduced into the individual.
  • DNA as used herein is defined as deoxyribonucleic acid.
  • Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
  • a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
  • Both the coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
  • endogenous refers to any material from or produced inside an organism, cell, tissue or system.
  • exogenous refers to any material introduced from or produced outside an organism, cell, tissue or system.
  • expression is defined as the transcription and/or translation of a particular nucleotide sequence driven by its promoter.
  • expression vector refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules, microRNA, siRNA, ribozymes, and the like.
  • Expression vectors can contain a variety of control sequences, which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operativeiy linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well.
  • heterologous as used herein is defined as DNA or RNA sequences or proteins that are derived from the different species.
  • Homologous refers to the subunit sequence similarity between two polymeric molecules, e.g., between two nucleic acid molecules, e.g., two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position.
  • the homology between two sequences is a direct function of the number of matching or homologous positions, e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two compound sequences are homologous then the two sequences are 50% homologous, if 90% of the positions, e.g., 9 of 10, are matched or
  • isolated nucleic acid refers to a nucleic acid segment or fragment which has been separated from sequences which flank it in a naturally occurring state, i.e., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, i.e., the sequences adjacent to the fragment in a genome in which it naturally occurs.
  • the term also applies to nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, i.e., RNA or DNA or proteins, which naturally accompany it in the cell.
  • the term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaiyote or eukaryote, or which exists as a separate molecule (i.e., as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence. It also includes a nucleic acid that have been removed from its native environment and placed in another, typically artificial, environment.
  • modulate is meant to refer to any change in biological state, i.e. increasing, decreasing, and the like.
  • modulate refers to the ability to regulate positively or negatively the expression or activity of BHD, Bim and/or other components of the TGFp- signaling pathway in a cell.
  • nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.
  • the phrase nucleotide sequence that encodes a protein or an RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).
  • polynucleotide as used herein is defined as a chain of nucleotides.
  • nucleic acids are polymers of nucleotides.
  • nucleic acids and nucleic acids are polymers of nucleotides.
  • polynucleotides as used herein are interchangeable.
  • nucleic acids are polynucleotides, which can be hydrolyzed into the monomelic "nucleotides.”
  • the monomelic nucleotides can be hydrolyzed into nucleosides.
  • polynucleotides include, but are not limited to, all nucleic acid sequences which are obtained by any means available in the art, including, without limitation, 2011/027507 recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCRTM, and the like, and by synthetic means,
  • polypeptide as used herein is defined as a chain of amino acid residues, usually having a defined sequence. As used herein the term polypeptide is mutually inclusive of the terms “peptide” and "protein”.
  • proliferation is used herein to refer to the reproduction or multiplication of similar forms of entities, for example proliferation of a cell, That is, proliferation encompasses production of a greater number of cells, and can be measured by, among other things, simply counting the numbers of cells, measuring incorporation of ⁇ H-thymidine into the cell, and the like.
  • promoter as used herein is defined as a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence,
  • promoter/regulatory sequence means a nucleic acid sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence.
  • this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product.
  • the promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue specific manner.
  • a “constitutive" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.
  • an “inducible" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell substantially only when an inducer which corresponds to the promoter is present in the cell.
  • tissue-specific promoter is a nucleotide sequence which, when operably linked with a polynucleotide encodes or specified by a gene, causes the gene product to be produced in a cell substantially only if the cell is a cell of the tissue type corresponding to the promoter,
  • RNA as used herein is defined as ribonucleic acid. 7
  • recombinant DNA as used herein is defined as DNA produced by joining pieces of DNA from different sources.
  • recombinant polypeptide as used herein is defined as a polypeptide produced by using recombinant DNA methods
  • “Fragment” as the term is used herein, is a nucleic acid sequence that differs in length (i.e., in the number of nucleotides) from the length of a reference nucleic acid sequence, but retains essential properties of the reference molecule.
  • a protein fragment can exist that is a part of a larger parent protein.
  • One example of a retained essential property would be the ability of the fragment nucleic acid to hybridize to a particular target mRNA, much like the reference nucleic acid sequence, and thereby diminish expression.
  • a fragment of a nucleic acid can be a naturally occurring or can be a fragment that is not known to occur naturally. Non-naturally occurring fragments of nucleic acids may be made by mutagenesis techniques or by direct synthesis.
  • the fragment is at least about 25% of the length of the reference nucleic acid sequence. More preferably, the fragment is at least about 35% of the length of the reference nucleic acid sequence. Even more preferably, the fragment is at least about 45% of the length of the reference nucleic acid sequence.
  • Variant is a nucleic acid sequence that differs in sequence from a reference nucleic acid sequence, but retains essential properties of the reference molecule.
  • One example of a retained essential property would be the ability of the variant nucleic acid to hybridize to a particular target mRNA, much like the reference nucleic acid sequence, and thereby diminish expression.
  • a variant of a nucleic acid can be a naturally occurring such as an allelic variant, or can be a variant that is not known to occur naturally. Non-naturally occurring variants of nucleic acids may be made by mutagenesis techniques or by direct synthesis.
  • the variant shares at least about 80% homology with the reference nucleic acid sequence. More preferably, the variant shares at least about 90% homology with the reference nucleic acid sequence. Even more preferably, the variant shares at least about 95% homology with the reference nucleic acid sequence.
  • substantially purified cell is a ceil that is essentially free of other cell types.
  • a substantially purified cell also refers to a cell which has been separated from other cell types with which it is normally associated in its naturally occurring state,
  • a population of substantially purified cells refers to a homogenous population of cells. In other instances, this term refers simply to cell that have been separated from the cells with which they are naturally associated in their natural state.
  • the cells are cultured in vitro. In other embodiments, the cells are not cultured in vitro. 27507
  • a "therapeutically effective amount” is the amount of a therapeutic composition sufficient to provide a beneficial effect to a mammal to which the composition is administered.
  • transfected or “transformed” or “transduced” as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
  • a “transfected” or “transformed” or “transduced” cell is one which has been transfected, transformed or transduced with exogenous nucleic acid.
  • the cell includes the primary subject cell and its progeny.
  • under transcriptional control or "operatively linked” as used herein means that the promoter is in the correct location and orientation in relation to a
  • polynucleotide to control the initiation of transcription by RNA polymerase and expression of the polynucleotide.
  • a “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell.
  • vectors are known in the art including, but not limited to, linear polynucleotides,
  • vector includes an autonomously replicating plasmid or a virus.
  • the term should also be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucieic acid into cells, such as, for example, poiylysine compounds, liposomes, and the like.
  • viral vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, and the like.
  • virus as used herein is defined as a particle consisting of nucleic acid (RNA or DNA) enclosed in a protein coat, with or without an outer lipid envelope, which is capable of replicating within a whole cell.
  • Xenogeneic refers to a graft derived from an animal of a different species.
  • a “conservative substitution” is the substitution of an amino acid with another amino acid with similar physical and chemical properties.
  • a “nonconservative substitution” is the substitution of an amino acid with another amino acid with dissimilar physical and chemical properties.
  • gene and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide.
  • the term "genetically engineered” refers to a modification of the inherent genetic material of a microorganism (e.g., one or more of the deletion such as a gene knockout, addition, or mutation of one or more nucleic acid residues within the genetic material), addition of exogenous genetic material to a microorganism (e.g., transgene, stable plasmid, integrating plasmid, naked genetic material, among other things), causing the microorganism to alter its genetic response due to external or internal signaling (e.g., environmental pressures, chemical pressures, among other things), or any combination of these or similar techniques for altering the overall genetic makeup of the organism.
  • exogenous genetic material e.g., transgene, stable plasmid, integrating plasmid, naked genetic material, among other things
  • external or internal signaling e.g., environmental pressures, chemical pressures, among other things
  • “Mutants,” “derivatives,” and “variants” of a polypeptide are polypeptides which may be modified or altered in one or more amino acids (or in one or more nucleotides) such that the peptide (or the nucleic acid) is not identical to the wild-type sequence, but has homology to the wild type polypeptide (or the nucleic acid).
  • a “mutation" of a polypeptide is a modification or lteration of one or more amino acids (or in one or more nucleotides) such that the peptide (or nucleic acid) is not identical to the sequences recited herein, but has homology to the wild type polypeptide (or the nucleic acid).
  • a "mutant form" of a gene is a gene which has been altered, either naturally or artificially, changing the base sequence of the gene, which results in a change in the amino acid sequence of an encoded polypeptide.
  • the change in the base sequence may be of several different types, including changes of one or more bases for different bases, small deletions, and small insertions. Mutations may also include transposon insertions that lead to attenuated activity, i.e., by resulting in expression of a truncated protein.
  • a normal form of a gene is a form commonly found in a natural population of an organism. Commonly a single form of a gene will predominate in natural populations. In general, such a gene is suitable as a normal form of a gene; however, other forms which provide similar functional characteristics may also be used as a normal gene.
  • engine refers to any manipulation of a cell that result in a detectable change in the cell, wherein the manipulation includes but is not limited to inserting a polynucleotide and/or polypeptide heterologous to the cell and mutating a polynucleotide and/or polypeptide native to the cell.
  • a polynucleotide or polypeptide is "heterologous" to a cell if it is not part of the polynucleotides and polypeptides expressed in the cell as it exists in nature, i.e., it is not part of the wild-type of that cell.
  • a polynucleotide or polypeptide is instead "native" to a cell if it is part of the polynucleotides and polypeptides expressed in the cell as it exists in nature, i.e., it is part of the wild-type of that cell.
  • a “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate.
  • a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
  • a disease or disorder is "alleviated” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, are reduced.
  • terapéutica treatment is a treatment administered to a subject in need thereof.
  • treat and treatment mean cause, or the act of causing, a postponement of development of a disorder and/or a reduction in the severity of symptoms that will or are expected to develop.
  • the terms further include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying metabolic causes of symptoms.
  • an effective amount when used to describe therapy to an individual, refers to the amount of a compound that results in a therapeutically useful effect.
  • mammals as in the subject of the treatment
  • mammals particularly non-human primates, e.g. apes and monkeys, and most particularly humans.
  • a "BHD-based tumor” is a tumor in which BHD protein is absent, and/or is insufficient and/or ineffective in its role in TGF- ⁇ dependent apoptosis prior to therapeutic treatment of the tumor cells.
  • TGF- ⁇ refers to transforming growth facter beta protein family.
  • TGF- ⁇ signaling pathway refers to the biochemical signaling mechanism involved in cellular processes such as cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions.
  • the TGF- ⁇ signaling pathway functions in both the adult organisms and the developing embryos.
  • BHD may also regulate other tumor suppressive target genes such as pi 5 and A4/-/(Hannon et at,, 1994, Nature 371(6494):257-261 ; Kortlever et ah, 2006, Nat Cell Biol 8(8): 877-884), which inhibit cell cycle and drive replicative senescence respectively, could drive tumor formation in BHD patients.
  • the apoptotic resistance caused by reduced Bim expression is independent of niTOR or ERK hyperactivation.
  • BHD is required for normal yolk sac and hematopoietic development, similar to TGFP receptor and ligand mutants, and also for normal expression of a broad spectrum of Smad target genes. Further, apoptotic resistance and Bim downregulation observed in hc ' cells is attributable to hypo-acetylation of TGFp target gene promoters.
  • the present invention contemplates a number of targeted therapies that have a corrective effect on apoptosis-resistant ceils.
  • the present invention encompasses compositions and methods for treating BHD-based tumors, as well as sporadic cases of cystic lung disease and renal cell carcinoma, by correcting a defective apoptotic function that correlates with the absence of BHD, pailtcuiary the failure to undergo apoptosis as a result of misregulated TGFp-mediated chromatin modifications at target gene promoters.
  • the methods of the invention are contemplated for use in a mammal, preferably, a human.
  • the present invention includes a gene therapy approach, and generally the use of nucleic acid compositions, for treating BHD-based tumors, as well as sporadic cases of cystic king disease and renal cell carcinoma, and associated symptoms.
  • the full-length BHD gene, cDNA or fragments thereof can be cloned into a vector for use a therapeutic agent in gene therapy.
  • Nucleotide sequences for BHD are known in the art and can be obtained from, patent publications and public databases containing nucleic acid sequences.
  • the full-length Bim gene, cDNA or fragments thereof can be cloned into a vector for use in gene therapy.
  • Nucleotide sequences for Bim are known in the art and can be obtained from patent publications and public databases containing nucleic acid sequences.
  • components of the TGF- ⁇ signaling pathway can be cloned into vectors for use in gene therapy.
  • Nucleotide sequences for components of the TGF- ⁇ signaling pathway are also known in the art and can be obtained from patent publications and public databases containing nucleic acid sequences.
  • inhibitors of components of the TGF- ⁇ signaling pathway, as well as components of TGF- ⁇ dependent apoptosis can be used to inhibit such components, such that inhibition of the component leads to the promotion of apoptosis in the 7507 targeted cells.
  • exemplary inhibitors can include, by non-limiting example, small interfering RNA (siR A), a microRNA, an antisense nucleic acid, a ribozyme, an expression vector encoding a transdominant negative mutant, an intracellular antibody, a peptide and a small molecule.
  • one way to decrease the mRNA and/or protein levels of a cell component is by reducing or inhibiting expression of the nucleic acid encoding the component.
  • the protein level of the component in a cell can also be decreased using a molecule or compound that inhibits or reduces gene expression such as, for example, an antisense molecule or a ribozyme.
  • the modulating sequence is an antisense nucleic acid sequence which is expressed by a plasmid vector
  • the antisense expressing vector is used to transfect a mammalian cell or the mammal itself, thereby causing reduced endogenous expression of a desired inliibitor of the component in the cell.
  • the invention should not be construed to be limited to inhibiting expression of a component by transfection of cells with antisense molecules. Rather, the invention encompasses other methods known in the art for inhibiting expression or activity of a protein in the cell including, but not limited to, the use of a ribozyme, the expression of a non-functional component (i.e. transdominant negative mutant) and use of an intracellular antibody.
  • Antisense molecules and their use for inhibiting gene expression are well known in the art (see, e.g., Cohen, 1989, In: Oligodeoxyribonucleotides, Antisense Inhibitors of Gene Expression, CRC Press).
  • Antisense nucleic acids are DNA or RNA molecules that are complementary, as that term is defined elsewhere herein, to at least a portion of a specific mRNA molecule (Weintraub, 1990, Scientific American 262:40), In the cell, antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule thereby inhibiting the translation of genes.
  • antisense methods to inhibit the translation of genes is known in the art, and is described, for example, in Marcus-Sakura (1988, Anal, Biochem. 172:289).
  • Such antisense molecules may be provided to the cell via genetic expression using DNA encoding the antisense molecule as taught by Inoue, 1993, U.S. Patent No. 5,190,931.
  • antisense molecules of the invention may be made synthetically and then provided to the cell.
  • Antisense oligomers of between about 10 to about 30, and more preferably about 15 nucleotides, are preferred, since they are easily synthesized and introduced into a target cell.
  • Synthetic antisense molecules contemplated by the invention include oligonucleotide derivatives known in the art which have improved biological activity compared to unmodified oligonucleotides (see U.S. Patent No. 5,023,243).
  • Ribozymes and their use for inhibiting gene expression are also well known in the art (see, e.g., Cech et al., 1992, J. Biol. Chem. 267: 17479- 17482; Hampel et al., 1989,
  • Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences encoding these RNAs, molecules can be engineered to recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, 1988, J. Amer. Med. Assn. 260:3030). A major advantage of this approach is the fact that ribozymes are sequence-specific.
  • ribozymes There are two basic types of ribozymes, namely, tetraiiymena-type (Hasselhoff, 1988, Nature 334:585) and hammerhead-type, Tetrahymena-type ribozymes recognize sequences which are four bases in length, while hammerhead-type ribozymes recognize base sequences 1 1-18 bases in length. The longer the sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating specific mRNA species, and 18-base recognition sequences are preferable to shorter recognition sequences which may occur randomly within various unrelated mRNA molecules.
  • Ribozymes useful for inhibiting the expression of a component may be designed by incorporating target sequences into the basic ribozyme structure which are complementary to the mRNA sequence of the desired component targeted by the present invention. Ribozymes targeting the desired component may be synthesized using commercially available reagents (Applied Biosystems, Inc., Foster City, CA) or they may be genetically expressed from DNA encoding them.
  • the component can be inhibited by way of inactivating and/or sequestering the component.
  • inhibiting the effects of a component can be accomplished by using a transdominant negative mutant.
  • an intracellular antibody specific for the desired component otherwise known as an antagonist to the component, may be used.
  • the antagonist is a protein and/or compound having the desirable property of interacting with a binding partner of the cytokine signaling regulator and thereby competing with the corresponding wild-type component
  • the antagonist is a protein and/or compound having the desirable property of interacting with the component and thereby sequestering the component.
  • siRNA small interfering RNA
  • siRNA encompasses all forms of siRNA including, but not limited to (i) a double stranded RNA polynucleotide, (ii) a single stranded polynucleotide, and (iii) a polynucleotide of either (i) or (ii) wherein such a polynucleotide, has one, two, three, four or more nucleotide alterations or substitutions therein.
  • An siRNA in the form of a double stranded polynucleotide comprises about 18 base pairs, about 19 base pairs, about 20 base pairs, about 21 base pairs, about 22 base pairs, about 23 base pairs, about 24 base pairs, about 25 base pairs, about 26 base pairs, about 27 base pairs, about 28 base pairs, about 29 base pairs or about 30 base pairs in length.
  • the double stranded siRNA capable of interfering with the expression and/or the activity of a targeted component as explained hereinthroughout.
  • a single stranded siRNA comprises a portion of an RNA polynucleotide sequence that is targeted to a gene or polynucleotide of interest.
  • a single stranded siRNA comprises a polynucleotide of about 18 nucleotides, about 19 nucleotides, about 20 nucleotides, about 21 nucleotides, about 22 nucleotides, about 23 nucleotides, about 24 nucleotides, about 25 nucleotides, about 26 nucleotides, about 27 nucleotides, about 28 nucleotides, about 29 nucleotides or about 30 nucleotides in length.
  • the single stranded siRNA is capable of interfering with expression and/or activity of a target polynucleotide, or a variant thereof.
  • the single strand siRNA is also capable of annealing to a complementary sequence to result in a dsRNA that is capable of interfering with the expression and/or the activity of a component.
  • the siRNA comprises a polynucleotide comprising either a double stranded or a single stranded polynucleotide, wherein the siRNA has one, two, three, four or more nucleotide alterations or substitutions therein.
  • siRNA polynucleotide is an RNA nucleic acid molecule that interferes with RNA activity that is generally considered to occur via a post-transcriptional gene silencing mechanism.
  • An siRNA polynucleotide preferably comprises a double-stranded RNA (dsRNA) but is not intended to be so limited and may comprise a single-stranded RNA (see, e.g., Martinez et a!., 2002 Cell 1 10:563-74).
  • siRNA polynucleotide included in the invention may comprise other naturally occurring, recombinant, or synthetic single-stranded or double-stranded polymers of nucleotides (ribonucleotides or deoxyribonucleotides or a combination of both) and/or nucleotide analogues as provided herein (e.g., an oligonucleotide 7507 or polynucleotide or the like, typically in 5' to 3' phosphodiester linkage).
  • nucleotides ribonucleotides or deoxyribonucleotides or a combination of both
  • nucleotide analogues as provided herein (e.g., an oligonucleotide 7507 or polynucleotide or the like, typically in 5' to 3' phosphodiester linkage).
  • siRNA may be transcribed using as a template a DNA (genomic, cDNA, or synthetic) that contains a promoter for an RNA polymerase promoter.
  • the promoter can be the U6 promoter or the HI RNA polj'merase ill promoter.
  • the siRNA may be a synthetically derived RNA molecule.
  • the siRNA polynucleotide may have blunt ends.
  • At least one strand of the siRNA polynucleotide has at least one, and preferably two nucleotides that "overhang" (i.e., that do not base pair with a complementary base in the opposing strand) at the 3' end of either strand of the siRNA polynucleotide.
  • each strand of the siRNA polynucleotide duplex has a two-nucleotide overhang at the 3' end.
  • the two- nucleotide overhang is preferably a thymidine dinucleotide (TT) but may also comprise other bases, for example, a TC dinucleotide or a TG dinucleotide, or any other dinucleotide.
  • the overhang dinucleotide may also be complementary to the two nucleotides at the 5' end of the sequence of the polynucleotide that is targeted for interference.
  • Preferred siRNA polynucleotides comprise double-stranded polynucleotides of about 1 8-30 nucleotide base pairs, preferably about 1 8, about 19, about 20, about 21 , about 22, about 23, about 24, about 25, about 26, or about 27 base pairs, and in other preferred embodiments about 1 , about 20, about 21 , about 22 or about 23 base pairs, or about 27 base pairs, whereby the use of "about” indicates that in certain embodiments and under certain conditions the processive cleavage steps that may give rise to functional siRNA
  • siRNA polynucleotides may include one or more siRNA polynucleotide molecules that may differ (e.g., by nucleotide insertion or deletion) in length by one, two, three, four or more base pairsas a consequence of the variability in processing, in biosynthesis, or in artificial synthesis of the siRNA.
  • the siRNA polynucleotide of the present invention may also comprise a polynucleotide sequence that exhibits variability by differing (e.g., by nucleotide substitution, including transition or transversion) at one, two, three or four nucleotides from a particular sequence.
  • siRNA polynucleotide sequence differs from any of the nucleotide positions of a particular siRNA polynucleotide sequence, depending on the U 2011/027507 length of the molecule, whether situated in a sense or in an antisense strand of the double- stranded polynucleotide,
  • the nucleotide difference may be found on one strand of a double- stranded polynucleotide, where the complementary nucleotide with which the substitute nucleotide would typically form hydrogen bond base pairing, may not necessarily be correspondingly substituted.
  • the siRNA polynucleotides are homogeneous with respect to a specific nucleotide sequence.
  • Polynucleotides that comprise the siRNA polynucleotides of the present invention may in certain embodiments be derived from a single-stranded polynucleotide that comprises a single-stranded oligonucleotide fragment (e.g., of about 18-30 nucleotides) and its reverse complement, typically separated by a spacer sequence.
  • cleavage of the spacer provides the single-stranded oligonucleotide fragment and its reverse complement, such that they may anneal to form, optionally with additional processing steps that may result in addition or removal of one, two, three or more nucleotides from the 3' end and/or the 5' end of either or both strands, the double-stranded siRNA polynucleotide of the present invention.
  • the spacer is of a length that permits the fragment and its reverse complement to anneal and form a double-stranded structure (e.g., like a hairpin polynucleotide) prior to cleavage of the spacer, and optionally, subsequent processing steps that may result in addition or removal of one, two, three, four, or more nucleotides from the 3' end and/or the 5' end of either or both strands.
  • a spacer sequence may therefore be any polynucleotide sequence as provided herein that is situated between two complementary polynucleotide sequence regions which, when annealed into a double-stranded nucleic acid, result in an siRNA polynucleotide.
  • the spacer sequence comprises at least 4 nucleotides
  • the spacer may comprise 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 -25, 26-30, 31-40, 41 -50, 51 -70, 71 - 90, 91 -1 10, 1 1 1- 150, 151 -200 or more nucleotides
  • Examples of siRNA polynucleotides derived from a single nucleotide strand comprising two complementary nucleotide sequences separated by a spacer have been described (e.g., Bmmmelkamp et al., 2002 Science 296:550; Paddison et al., 2002 Genes Develop. 16:948; Paul et al., 2002 Nat. Biotechnoi. 20:505-508; Grabarek et al., 2003 BioTechniques 34:734-44).
  • Polynucleotide variants may contain one or more substitutions, additions, deletions, and/or insertions such that the activity of the siRNA polynucleotide is not substantially diminished, The effect of any such alterations in nucleotide content on the activity of the siRNA polynucleotide may generally be assessed as described elsewhere herein.
  • Variants preferably exhibit at least about 75%, 78%, 80%, 85%, 87%, 88% or 89% identity and more preferably at least about 90%, 92%, 95%, 96%, or 97% identity to a portion of a
  • polynucleotide sequence that encodes a native protein component The percent identity may be readily determined by comparing sequences of the polynucleotides to the corresponding portion of the target polynucleotide, using any method including using computer algorithms well known to those having ordinary skill in the art, These include the Align or the BLAST algorithm (Altschul, 1991 J. Mol. Biol. 219:555-565; Henikoff and Henikoff, 1992, Proc. Natl. Acad. Sci. USA 89: 10915- 10919).
  • siRNA polynucleotide variants can be substantially homologous to a portion of a polynucleotide encoding a target polypeptide .
  • Single-stranded polynucleotides derived from these polynucleotide variants are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA or RNA sequence encoding the target polypeptide.
  • siRNA polynucleotide that detectably hybridizes to the polynucleotide sequence encoding the target polypeptide under moderately stringent conditions may have a nucleotide sequence that includes at least 10 consecutive nucleotides, more preferably 1 1 , 12, 13, 1 , 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides that are complementary to a particular target polynucleotide.
  • such an siRNA sequence (or its complement) will be unique to a single particular polynucleotide encoding the target polypeptide for which interference with expression is desired.
  • the sequence (or its complement) may be shared by two or more related polynucleotides encoding the target polypeptide for which interference with polypeptide expression is desired.
  • Suitable moderate stringent conditions include, for example, pre-washing the polynucleotide in a solution of 5X SSC, 0.5% SDS, 1 ,0 mM EDTA (pH 8.0); hybridizing the polynucleotide at 50°C-70°C, 5X SSC for 1-16 hours (e.g., overnight); followed by washing the polynucleotide once or twice at 22-65°C for 20-40 minutes with one or more each of 2X, 0.5X and 0.2X SSC containing 0.05-0.1% SDS.
  • hybridization conditions may include an additional wash in 0.1X SSC and 0.1% SDS at 50-60°C for 15-40 minutes.
  • hybridization conditions may be achieved by altering the time, temperature, and/or concentration of the solutions used for the pre-hybridization, hybridization, and wash steps. Suitable conditions may also depend in part on the particular nucleotide sequences of the probe used, and of the blotted, proband nucleic acid sample. Accordingly, it will be appreciated that suitably stringent conditions can be readily selected, without undue experimentation, when a desired selectivity of the polynucleotide is identified, based on its ability to hybridize to one or more certain proband sequences while not hybridizing to certain other proband sequences.
  • Sequence specific siRNA polynucleotides of the present invention may be designed using one or more of several criteria. For example, to design an siRNA polynucleotide that has about 21 consecutive nucleotides identical to a sequence encoding a polypeptide of interest, the open reading frame of the polynucleotide sequence may be scanned for about 21 - base sequences length that have one or more of the following characteristics: ( 1 ) an
  • an siRNA polynucleotide sequence may be designed and chosen using a computer software available commercially from various vendors, e.g., OligoEngine.TM.
  • siRNA polynucleotide may then be tested for the ability to interfere with the expression of the target polypeptide according to methods known in the art and described elsewherein herein.
  • the determination of the effectiveness of an siRNA polynucleotide includes not only consideration of its ability to interfere with the expression of the target polypeptide, but also whether the siRNA polynucleotide is toxic to the host cell. For example, a desireable siRNA would exhibit an RNA interference activity and would also not exhibit an unwanted biological consequence.
  • the siRNAs may effect silencing of the target polypeptide expression to different degrees.
  • the siRNAs thus must first be tested for their effectiveness. Selection of siRNAs are made therefrom based on the ability of a given siRNA to interfere with or modulate the expression of the target polypeptide. Accordingly, identification of specific siRNA polynucleotide sequences that are capable of interfering with expression of a desired target polypeptide requires production and testing of each siRNA.
  • nucleotide sequences may encode the same polypeptide. That is, an amino acid may be encoded by one of several different codons, and a person skilled in the art can readily determine that while one particular nucleotide sequence may differ from another, the polynucleotides may in fact encode polypeptides with identical amino acid sequences. As such, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention.
  • Polynucleotides of the siRNA may be prepared using any of a variety of techniques, which are useful for the preparation of specifically desired siRNA polynucleotides.
  • a polynucleotide may be amplified from a cDNA prepared from a suitable cell or tissue type.
  • Such a polynucleotide may be amplified via polymerase chain reaction (PCR), Using this approach, sequence-specific primers are designed based on the sequences provided herein, and may be purchased or synthesized directly. An amplified portion of the primer may be used to isolate a full-length gene, or a desired portion thereof, from a suitable DNA library using well known techniques.
  • PCR polymerase chain reaction
  • a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification.
  • the library is size-selected to include larger polynucleotide squences. Random primed libraries may also be preferred in order to identify 5' and other upstream regions of the genes, Genomic libraries are preferred for obtaining introns and extending 5' sequences.
  • the siRNA polynucleotide contemplated by the present invention may also be selected from a library of siRNA polynucleotide sequences.
  • a partial polynucleotide sequence may be labeled (e.g., by nick-translation or end-labeling with 32 P) using well known techniques, A bacterial or bacteriophage library may then be screened by hybridization to filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see, e.g., Sambrook et ai., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
  • Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis.
  • siRNA polynucleotides may generally be prepared by any method known in the art, including, for example, solid phase chemical synthesis. Modifications in a polynucleotide sequence may also be introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis. Further, siRNAs may be chemically modified or conjugated with other molecules to improve their stability and/or delivery properties, Included as one aspect of the invention are siRNAs as described herein, wherein one or more ribose sugars has been removed therefrom.
  • siRNA polynucleotide molecules may be generated by in vitro or in vivo transcription of suitable DNA sequences (e.g., polynucleotide sequences encoding a target polypeptide, or a desired portion thereof), provided that the DNA is incorporated into a vector with a suitable RNA polymerase promoter (such as for example, T7, U6, HI , or SP6 although other promoters may be equally useful).
  • RNA polymerase promoter such as for example, T7, U6, HI , or SP6 although other promoters may be equally useful.
  • an siRNA polynucleotide may be administered to a mammal, as may be a DNA sequence (e.g., a recombinant nucleic acid construct as provided herein) that supports transcription (and optionally appropriate processing steps) such that a desired siRNA is generated in vivo,
  • an siRNA polynucleotide wherein the siRNA polynucleotide is capable of interfering with expression of a target polypeptide can be used to generate a silenced cell for the targeted polypeptide.
  • Any siRNA polynucleotide that, when contacted with a biological source for a period of time, results in a significant decrease in the expression of the target polypeptide is included in the invention.
  • the decrease is greater than about 10%, more preferably greater than about 20%, more preferabiy greater than about 30%, more preferably greater than about 40%, about 50%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or about 98% relative to the expression level of the target polypeptide detected in the absence of the siRNA.
  • the siRNA polynucleotide that, when contacted with a biological source for a period of time, results in a significant decrease in the expression of the target polypeptide.
  • the decrease is about 10%-20%, more preferably about 20%- 30%), more preferably about 30%-40%, more preferably about 40%-50%, more preferably about 50%-60%, more prefereably about 60%-70%, more preferabiy about 70%-80%, more preferably about 80%-90%, more preferably about 90%-95%, more preferably about 95%- 98% relative to the expression level of the target polypeptide detected in the absence of the siRNA.
  • the siRNA polynucleotide that, when contacted with a biological source for a period of time, results in a significant decrease in the expression of the target polypeptide.
  • the decrease is about 10%» or more, more preferably about 20% or more, more preferably about 30% or more, more preferably about 40%» or more, more preferably about 50% or more, more preferably about 60% or more, more preferably about 70% or more, more preferably about 80% or more, more preferably about 90%> or more, more preferably about 95 % or more, more preferably about 98% or more relative to the expression level of the target polypeptide detected in the absence of the siRNA.
  • the siRNA polynucleotide will have certain characteristics that can be modified to improve the siRNA as a therapeutic compound. Therefore, the siRNA polynucleotide may be further designed to resist degradation by modifying it to include phosphorothioate, or other linkages, methylphosphonate, sulfone, sulfate, ketyl,
  • Any polynucleotide may be further modified to increase its stability in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodi ester linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine, and wybutosine and the like, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine, and uridine.
  • retroviruses can be used as a vector for gene therapy, for a high efficiency of infection and stable integration and expression (Orkin et ai., Prog. Med. Genet. 7: 130-142, 1988).
  • other viral transfection systems may be utilized, including (without limitation) adenovirus, adeno-associated virus (AAV) (McLaughlin et al., J, Virol. 62: 1963- 1973, 1988), Vaccinia virus (Moss et al., Annu. Rev. Immunol. 5:305-324, 1 987), Bovine Papilloma virus (Rasmussen et al., Methods Enzymol. 139:642-654, 1987) or members of the herpesvirus group such as Epstein-Barr virus (Margolskee et al., Mol. Cell. Bioi. 8:2837-2847, 1988).
  • AAV adeno-associated virus
  • Vaccinia virus Moss et al
  • RNA-DNA hybrid oligonucleotides as described by Cole-Strauss, et l, (Science 273: 1386-1389, 1996) can be used. Such techniques may allow for site-specific integration of cloned sequences, thereby permitting accurately targeted gene replacement.
  • non-infectious methods of delivery can be used, such as lipidic and liposome-mediated gene delivery for transfection with various genes (for reviews, see Templeton and Lasic, Mol. Biotechnol. 1 1 : 175-180, 1999; Lee and Huang, Crit. Rev. Ther. Drug Carrier Syst. 14: 173-206; and Cooper, Semin. Oncol. 23: 172-187, 1996).
  • cationic liposomes have been analyzed for their ability to transfect monocytic leukemia cells, and shown to be a viable alternative to using viral vectors (de Lima et al., Mol. Membr. Biol, 16: 103- 109, 1999).
  • Such cationic liposomes can also be targeted to specific cells through the inclusion of, for instance, monoclonal antibodies or other appropriate targeting ligands ( ao et al., Cancer Gene Ther. 3:250-256, 1996).
  • the present invention also includes compositions including therapeutic agents that promote and/or induce apoptosis in BHD-based tumors, cystic lung disease and renal cell carcinoma, and associated disease.
  • the compositions include a therapeutically effective amount of a BH3-only peptide or protein, or a BH3-only mimetic.
  • BH3-only proteins connect various stress stimuli to the Bcl-2-family-regulated, common mechanism of apoptosis.
  • Non-limiting examples of BH3-only peptides or proteins can include BID, BIM, BAD and/or NOXA, or fragments thereof, while non-limiting examples of BH3-only mimetics can include ABT-737.
  • compositions can include a therapeutically effective amount of a histone deacety!ase (HDAC) inhibitor.
  • HDACs function as part of large multiprotein complexes, which are tethered to the promoter and repress transcription, thereby reducing uncontrolled cell proliferation.
  • HDAC inhibitors of the present invention include Trichostatin and Vorinostat.
  • the compositons may include autophagy inhibitors, such as chlo oquine and 3-MA.
  • the present invention is based, in part, on the novel discovery that tumor formation in BHD patients results, at least in part, from a lack of TGFp-mediated Bim transcription and consequent apoptotic resistance. Particularly, apoptotic resistance and Bim downregulation is attributable to hypo-acetylation of TGF target gene promoters.
  • the present invention contemplates a number of targeted therapies that can be used as a treatment for a BHD-based tumor in a mammal.
  • the most preferred mammal is a human.
  • TGF- ⁇ dependent apoptosis provides an important and novel therapeutic for the treatment of BHD-based tumors, as well as sporadic cases of cystic lung disease and renal cell carcinoma,
  • a therapeutic composition as described above, is administered to a mammal, thereby promoting or inducing apoptosis in the targeted cells and providing a tlierapeutic benefit.
  • the therapeutic compositions can promote or induce apoptosis using a wide range of techniques known or to be developed in the future. That is, the invention encompasses promoting and/or inducing TGF- ⁇ dependent apoptosis in a mammal, and thereby preventing the progression and invasiveness of a BHD-based tumor.
  • the present invention discloses methods for promoting and/or inducing TGF-p dependent apoptosis in a mammal, e.g.
  • BH3-only molecules BH3-only molecules, HDAC inhibitors, autophagy inhibitors, and expressing or administering a gene therapy vectors encoding BHD, Bim or a component of the TGF- ⁇ signaling pathway.
  • affecting TGF- ⁇ dependent apoptosis mediates a variety of effects, including, but not limited to decreased tumor size and increased survival time in mammals afflicted with BHD-based tumors, and thereby provides a novel and powerful therapeutic.
  • cells are isolated from a mammal (preferably a human) and modified to promote and/or induce TGF- ⁇ dependent apoptosis according to the methods of the invention.
  • the cell is modified to have a component of BHD or Bim activated, expressed or upregulated, a component of the TGF- ⁇ signaling pathway activated or inactivated, or any combinations thereof.
  • the heighted cell can be administered to a mammalian recipient to provide a therapeutic benefit.
  • the mammalian recipient may be a human and the cell so modified can be autologous with respect to the recipient.
  • the cells can be allogeneic, syngeneic or xenogeneic with respect to the recipient.
  • the procedure for ex vivo expansion is known and understood by those skilled in the art, and therefore the present invention is not limited to any particular method of ex vivo expansion of the cells.
  • the present invention also provides compositions and methods for in vivo therapy to promote and/or induce TGF- ⁇ dependent apoptosis.
  • the present invention provides a component of BHD or Bim activated, expressed or upregulated, a component of the TGF- ⁇ signaling pathway activated or inactivated, or any combinations thereof.
  • the cell-based therapy used for in vivo immunization comprises an inhibitor component, an activator component, or any combination thereof, wherein the cell-based therapy is able to promote and/or induce TGF- ⁇ dependent apoptosis,
  • a vector into a cell in gene therapy examples include: (1) methods utilizing physical means, such as electroporation (electricity), a gene gun (physical force) or applying large volumes of a liquid (pressure); and (2) methods wherein said vector is complexed to another entity', such as a nanoparticle including but not limited to a liposome, an aggregated protein or a transporter molecule.
  • physical means such as electroporation (electricity), a gene gun (physical force) or applying large volumes of a liquid (pressure)
  • a nanoparticle including but not limited to a liposome, an aggregated protein or a transporter molecule.
  • Cells containing the desired nucleic acid may also contain a suicide gene i.e., a gene which encodes a product that can be used to destroy the cell.
  • a suicide gene i.e., a gene which encodes a product that can be used to destroy the cell.
  • the nucleic acid sequence corresponding to the inhibitor and/or activator of the invention can be linked to a suicide gene, whose expression is not activated in the absence of a suicide gene activator compound.
  • the suicide gene activator compound is administered to the ceil thereby activating expression of the suicide gene and killing the ceil.
  • suicide gene/prodrug combinations examples include herpes simplex virus-thymidine kinase (HSV-tk) and ganciclovir, acyclovir; oxtdorediictase and cycloheximide; cytosine deaminase and 5-fluorocytosme; thymidine kinase thymidilate kinase (Tdk::Tmk) and AZT; and deoxycytidine kinase and cytosine arabinoside,
  • the compounds of the present invention may be used in combination with existing therapeutic agents used to treat BHD syndrome, particularly BHD- based tumors, as well as sporadic cases of cystic lung disease and renai cell carcinoma. In some instances, the compounds of the invention may be used in combination with these therapeutic agents to enhance the therapeutic effect of the therapeutic agent.
  • an effective amount of a compound of the invention and an existing therapeutic agent is a synergistic amount.
  • a "synergistic" As used herein, a "synergistic
  • combination or a "synergistic amount" of a compound of the invention and an existing therapeutic agent is a combination or amount that is more effective in the therapeutic or prophylactic treatment of a disease than the incremental improvement in treatment outcome that could be predicted or expected from a merely additive combination of (i) the therapeutic or prophylactic benefit of the compound of the invention when administered at that same dosage as a monotherapy and (ii) the therapeutic or prophylactic benefit of the therapeutic agent when administered at the same dosage as a monotherapy.
  • the present invention envisions treating a disease, such as cancer, cystic lung disease and the like, in a mammal by the administration of a therapeutic agent, as described herein.
  • Administration of the therapeutic agent in accordance with the present invention may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
  • the administration of the agents of the invention may be essentially continuous over a preselected period of time or may be in a series of spaced doses. Both local and systemic administration is contemplated.
  • the amount administered will vary depending on various factors including, but not limited to, the composition chosen, the particular disease, the weight, the physical condition, and the age of the mammal, and whether prevention or treatment is to be achieved. Such factors can be readily determined by the clinician employing animal models or other test systems which are well known to the art. Pharmaceutical formulations, dosages and routes of administration for nucleic acids are generally disclosed, for example, in Feigner et al., supra
  • One or more suitable unit dosage forms having the therapeutic agent(s) of the invention can be administered by a variety of routes including parenteral, including by intravenous and intramuscular routes, as well as by direct injection into the diseased tissue.
  • the therapeutic agent may be directly injected into the tumor.
  • the formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known to pharmacy. Such methods may include the step of bringing into association the therapeutic agent with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping the product into the desired delivery system.
  • the therapeutic agents of the invention are prepared for administration, they are preferably combined with a pharmaceutically acceptable carrier, diluent or excipient to form P T/US2011/027507 a pharmaceutical formulation, or unit dosage form.
  • a pharmaceutically acceptable carrier diluent or excipient to form P T/US2011/027507 a pharmaceutical formulation, or unit dosage form.
  • the total active ingredients in such formulations include from 0.1 to 99.9% by weight of the formulation.
  • a "pharmaceutically acceptable” is a carrier, diluent, excipient, and/or salt that is compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
  • the active ingredient for administration may be present as a powder or as granules; as a solution, a suspension or an emulsion.
  • compositions containing the therapeutic agents of the invention can be prepared by procedures known in the art using well known and readily available ingredients.
  • the therapeutic agents of the invention can also be formulated as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes.
  • the pharmaceutical formulations of the therapeutic agents of the invention can also take the form of an aqueous or anhydrous solution or dispersion, or alternatively the form of an emulsion or suspension.
  • the therapeutic agent may be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative.
  • the active ingredients may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain
  • formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen- free water, before use.
  • the unit content of active ingredient or ingredients contained in an individual aerosol dose of each dosage form need not in itself constitute an effective amount for treating the particular indication or disease since the necessary effective amount can be reached by administration of a plurality of dosage units. Moreover, the effective amount may be achieved using less than the dose in the dosage form, either individually, or in a series of administrations.
  • the pharmaceutical formulations of the present invention may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, soktbilizing or emulsifying agents, and salts of the type that are well-known in the art.
  • pharmaceutically acceptable carriers such as phosphate buffered saline solutions pH 7.0-8.0.
  • the active ingredients of this invention can be formulated and administered to treat a variety of disease states by any means that produces contact of the active ingredient with the agent's site of action in the body of the organism. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • water suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration contain the active ingredient, suitable stabilizing agents and, if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisuifate, sodium sulfite or ascorbic acid, either atone or combined, are suitable stabilizing agents.
  • Ethylenediaminetetraacetic acid EDTA
  • parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field.
  • the active ingredients of the invention may be formulated to be suspended in a pharmaceutically acceptable composition suitable for use in mammals and in particular, in humans.
  • a pharmaceutically acceptable composition suitable for use in mammals and in particular, in humans.
  • Such formulations include the use of adjuvants such as nniramy! dipeptide derivatives (MDP) or analogs that are described in U.S. Patent Nos. 4,082,735; 4,082,736; 4, 101 ,536; 4, 185,089; 4,235,771 ; and 4,406,890.
  • adjuvants which are useful, include alum (Pierce Chemical Co.), lipid A, trehalose dimycolate and
  • DDA dimethyldioctadecyiammonium bromide
  • IL- 12 IL- 12.
  • Other components may include a polyoxypropylene-polyoxyethylene block polymer (Pluronic®), a non-ionic surfactant, and a metabolizable oil such as squalene (U.S. Patent No. 4,606,91 8).
  • control release preparations can include appropriate macromolecu!es, for example polymers, polyesters, polyamino acids, polyvinyl, pyrolidone, ethylenevinylacetate, methyl cellulose, carboxy methyl cellulose or protamine sulfate.
  • concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release.
  • the agent can be incorporated into particles of polymeric materials such as polyesters, polyamino acids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.
  • the pharmaceutical composition of the present invention may be delivered via various routes and to various sites in an mammal body to achieve a particular effect (see, e.g., Rosenfeid et al., 1 91 ; Rosenfeld et al., 1991a; Jaffe et al., supra; Berkner, supra).
  • Rosenfeid et al. 1 91
  • Rosenfeld et al. 1991a
  • Jaffe et al., supra Berkner, supra.
  • One skilled in the art will recognize that although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. Local or systemic delivery can be accomplished by
  • administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising
  • each dosage unit e.g., a teaspoonful, tablet, solution, or suppository
  • each dosage unit e.g., a teaspoonful, tablet, solution, or suppository
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human and mammal subjects, each unit containing a predetermined quantity of the compositions of the present invention, alone or in combination with other active agents, calculated in an amount sufficient to produce the desired effect, in association with a pharmaceutically acceptable diluent, carrier, or vehicle, where appropriate.
  • the specifications for the unit dosage forms of the present invention depend on the particular effect to be achieved and the particular pharmacodynamics associated with the
  • composition in the particular host.
  • compositions can be further approximated through analogy to compounds known to exert the desired effect.
  • Bim and BHD have each been siiown to play roles in polycystic kidney disease in independent mouse knock-out models (Bouttlet et al, 2001 , Dev Ceil I (5):645 ⁇ 653; Baba et al, 2008, J Natl Cancer Inst 100(2): 140- 1 54).
  • BHD BHD regulates apoptosis through interaction with the TGFp pathway, which is an especially attractive candidate pathway for several reasons.
  • the BHD fly ortholog has been suggested to act as a positive effector downstream of the TGFp family member Decapentapkgic (Dpp) in Drosophila (Singh et al, 2006, Oncogene 25(44):5933-5941 ).
  • Dpp Decapentapkgic
  • TGFp signaling components appear to be downregulated in many human cancers.
  • Srnac/4 germiine mutations are associated with juvenile polyposis syndrome which predisposes individuals to gastrointestinal cancers, and TGF RI, TGFfiRII and activin receptor II e mutated or downregulated in a broad spectrum of sporadic cancers (Levy et al, 2006, Cytokine Growth Factor Rev 17( l -2):4 l -58).
  • Epigenetic silencing of genes involved in TGFp signaling have also specifically been observed in renal cell carcinomas (McRona!d et l, 2009, Mol Cancel ⁇ s' 1 ). Genetic ablation of these signaling components in mice have confirmed the tumor suppressive function of this pathway in models of colon, mammary and pancreatic cancer (Massague, 2008, Cell 134(2):2i5-230).
  • Bhd A ES cells have many molecular and phenotypic defects in Bhd A ES cells, including decreased expression of many canonical Smad targets as well as in vitro hematopoietic and yolk sac defects. It is also probable that the reduced size of Bhd cells is due to loss of TGFp-mediated transcriptional effects on cellular hypertrophy as the TGFp pathway has previously been reported to drive cell growth (Wu et al, 2009, Dev Cell 17(l):35-48). Clearly, the yolk sac and hematopoietic defects observed in Bhd' ⁇ EBs cannot explain the early lethality of Bhd nfm embryos.
  • BHD may also regulate other tumor suppressive target genes such as j/5 and PAI-l(H non et al, 1994, Nature 371 (6494):257-261 ; ortlever et al., 2006, Nat Cell Biol 8(8):877-884), which inhibit cell cycle and drive replicative senescence respectively, could drive tumor formation in BHD patients.
  • Embryonic stem cell culture and treatments For in vitro studies, ES cells were adapted to gelatin, maintained in DMEM supplemented with 15% FBS, LIF, BME, nonessential amino acids and L-glutamine, split at a maximal dilution of 1 :7, and all experiments were performed on low passage number cell lines. To generate Bhd and Bhc " /m ES cell clones, Bhc 1' cells were selected on 1 mg/mL and Bh /m on 8 mg/mL G418 for two weeks, after which clones were picked, genotyped and expanded. For serum deprivation, cells were deprived of FBS as well as LIF for 24 hours.
  • cells were either deprived of all glucose or all amino acids respectively in the presence of dialyzed serum and LIF for indicated times.
  • TNF treatment cells were cultured in 50 ng/mL TNF in combination with 10 ⁇ cycloheximide for 24 hours.
  • 5 ⁇ LY294002, 10 ⁇ PD98059, 20nM rapamycin or 10 nM TSA were aii administered for 6 hours prior to amino acid deprivation, then read ministered 24 hours later, to maintain constant concentrations until harvesting.
  • cells were cultured in N2B27 media as previously described (Ying et al., 2003, Cell 1 15(3):281 ⁇ 292), then treated with 10 ng/mL recombinant activin for 30 minutes to assess Smad phosphorylation, one hour to assess acetyl-H3 by ChIP or two hours to assess Bim mRNA induction.
  • Bhc /m ES cells were obtained from Bay Genomics and Bhct' ' ES cells were obtained from the German Gene Trap
  • Bhct /m mice were generated as previously described (Hartman et al, 2009, Oncogene 28(13): 1594- 1604) and Bhct m intercrosses and embryo collection were performed as previously described (Covello et al, 2006, Genes Dev 20(5):557-570).
  • X-Gai staining of tissues and embryos was carried out as previously described for both cells and whole mount tissues fixed in 4% p rafomaldehyde, according to the Sanger Institute gene trap protocol. X-gal stained yolk sac sections came from tissue snap-frozen in O.CT.
  • RNA isolation and quantitative real-time PCR RNA was extracted using Qiagen RNeasy columns with DNAase treatment, and cDNA was written off approximately I ⁇ g of RNA per reaction using the ABT one-step RT-PCR Master Mix. qRT-PCR reactions were run in triplicate on an ABI 7900HT machine for each experiment, utilizing either SYBR green or Taqman primer probe sets as noted in the Supplementary Materials. All target mRNA levels were normalized to ⁇ -actin or 18s expression levels. All qRT-PCR data reflects average mRNA levels from three independent RNA extractions and reverse transcription reactions with error bars showing standard error of the mean.
  • Alkaline phosphatase staining Cells were stained using the Alkaline Phosphatase Detection Kit from Millipore according to manufacturer's instructions.
  • Protein extraction and western blotting Whole cell tysates were prepared using a buffer containing 120 mM NaCl, 1 niM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 50 niM NaF, 1 % Triton and freshly added protease inhibitor cocktail tablets from Roche and 2 inM orthovanadate, Nuclear extracts were prepared using the Active Motif Nuclear Extraction kit, with 500 niM NaCl added after nuclease digestion followed by sonication of nuclear extracts.
  • Lysates were run on polyacrylamide gels, tiansfenered to nitrocellulose, blotted using standard protocols, and visualized on film using HRP-conjugated antibodies and ECL reagent, Rabbit polyclonal anti-BHD raised against the carboxy-terminal 20 amino acids of murine BHD was generated and affinity purified by Quality Control Biosystems.
  • Cell size measurements Cell size was measured using a Z2 Coulter particle size analyzer, At least 10,000 cells were measured for each experiment.
  • Proliferation assay 5 x 10 4 cells were plated in a gelatinized 12 well plate and counted using the Countess automatic counter from Invitrogen.
  • Paraffin-embedded patient samples were obtained from the Pathology archives at the University of Pennsylvania and patient identifiers were removed before analysis. Protocols were approved by the University of Pennsylvania Institutional Review Board.
  • Methylceilulose cultures and benezidiene staining were performed as previously described (Cooper el al., 1 74, Proc Natl Acad Sci USA 71(5): 1677- 1680; Adelman et ai, 1999, Genes Dev 13(i9):2478-2483).
  • Northern blotting Northern blots for miRNAs were done as previously described (Gruber et ⁇ , 2009, Cell 138(2):328-339).
  • Chromatin immunoprecipitation 1 x 10 6 ES cells were fixed for 10 minutes in 1 % formaldehyde for 10 minutes at room temperature. Crosslinking was quenched with 125 niM glycine for 5 minutes, then cells were Jysed and sonicated to shear DNA for 3 minutes with on/off pulses using a Fisher Sonic Dismembranator Model 500 at 20% power. Chromatin immunoprecipitation was carried using the Imgenex QuikChlP kit according to
  • Example 1 Homozygous mutant JMembrvos die during early embryogetiesis
  • MEFs mouse embryonic fibroblasts
  • Bh ⁇ f /m intercrosses yielded no viable Bhd' " embryos after e7.5. Although the e6.5 embryos could not be genotyped, it was observed that approximately 25% of these were severely abnormal or partially resorbed upon dissection, as depicted in Figure IF. As depicted in Figure 1 G, cross sections of these defective embryos revealed grossly atrophied and disorganized egg cylinders, containing distorted visceral endoderm and lack of cavitation. This phenotype is consistent with a recently-reported embryonic lethal phenotype for an independent mutant Bhd allele (Hasumi et a!. , 2009, Proc Natl Acad Sci USA
  • Example 2 Loss of BHD does not affect p ol iteration, but results in decreased cellular size and resistance to cell-intrinsic apoptosis
  • Bhd mR A levels were approximately 40-50% of those in Bhd + ceils, as shown by qRT-PCR using primers spanning multiple Bhd exons (Figure 2D), ⁇ -geo expression driven off the trap cassette was also verified in Bh( cells by X-Gal staining, as depiected in Figure 2E.
  • Bhd vA cells were plated in high concentrations of G418, and several independent cell lines were isolated, denoted as “ 1 ", "2" and “3".
  • PCR genotyping verified genomic loss of the wild-type allele in these lines, and Western blot confirmed complete loss of BHD protein expression, as depicted in Figures 3A and 3B,
  • levels of Oct-4, Nanog and Sox2 pluripotency factors were analyzed by Western blot and equivalent expression in Bhc /+ , Bh A and Bhd A cell lines were observed, as depicted in Figure 4A.
  • Bhd w+ , Bhc A and Bhd ES cell lines were assessed for proliferation, cell growth and apoptotic responses.
  • Bhd ES cells did not proliferate significantly faster at days 1 -3 after plating, but confluent cultures analyzed at day 4 were found to contain 15-20% more cells compared to Bhc /+ and Bh A counterparts, as depicted in Figure 3C. This difference was attributed to a 15-20% decrease in cellular volume in Bhd cells, as depicted in Figure 3D. While this reduced size phenotype is interesting and statistically significant, it appears inconsistent with a role for BHD in tumor suppression.
  • Bhd ES cells clearly demonstrated a clear resistance to all three apoptosis-inducing stresses, as revealed by light microscopy (depicted in Figure 3E), and confirmed by flow cytometric assessement of sub- G l populations, in addition, cleavage of caspase-3 and parp was also significantly reduced in Bhd 1' cells, following nutrient starvation compared to ⁇ ⁇ controls, as depicted in Figure 3H. This effect was specific to the intrinsic apoptotic pathway, as Bhd A cells showed no differential response to the death-receptor ligand TNFa, as depicted in Figures 3F and 3G.
  • BHD deficiency does not confer an obvious increase in cellular proliferation or growth, but does reduce cell-intrinsic apoptosss, thereby identifying a plausible cellular role for BHD as a tumor suppressor.
  • Example 3 Bim expression is lost in Bhd cells and BHD-related tumors and contributes to apoptotic resistance
  • Bhd A cells can either be due to increased intracellular nutrient stores, allowing them to withstand starvation, or result from a defect in the cell-intrinsic death machinery.
  • levels of thirteen different intracellular amino acids were evaluated by high performance liquid chromatography in Bhc /+ and Bhd 1' ES ceils, as mutation of S. pombe BHD resulted in increased intracellular stores of glutamate, citrulline and ornithine (van Sightenhorst et ⁇ , 2007, J Biol Chem 282(34):24583-24590).
  • Bh( /+ and Bhd A ES cells had comparable levels of ail intracellular amino acids tested, including arginine and glutamate, suggesting that nutrient homeostasis was not playing a role in the apoptotic resistance phenotype, as depicted in Figure 5A.
  • protein levels of the major pro-survival and pro-apoptotic Bcl2 family members were examined, as well as several BH3-only pro-apoptotic proteins, Amongst the major Bcl2 family members, ES cells were found to most highly express Bak and BclXL, the levels of which were unaltered in Bhd' ' ES cells.
  • Bim regulation in subsequent experiments was focused on, given its dominant role amongst BH3-only proteins in mediating the cell-intrinsic death response and frequent loss in renal cell carcinoma (Kim et a]. , 2006, Nat Cell Biol 8(12): 1348-1358; Zantl et al., 2007, Oncogene 26(49):7038-7048; Guo et al, 2009, Oncogene 28(16): 1864- 1874). Additionally, Bim has been shown to play an important role in murine models of polycystic kidney disease (Bouillet et al.
  • BimEL or Bhd expression was restored by retroviral transduction in Bhd' ' ES cells.
  • Bh reconstitution was sufficient to restore Bim protein levels.
  • Example 4 Bim is transcriptionally downregulated in Bhd J ⁇ cells independent of inTORC 1 , mTORC2, ERK. or GCN2-eIF2a pathway misreeulation
  • Bim mRNA is regulated transcriptionally by several well-characterized signal transduction pathways, t anslattonally by miRNAs, and on the level of protein stability (Dijkers e/ i?/., 2000, Curr Biol 10(19): 1201 - 1204; Dehan et a!. , 2009, Mol Cell 33(1): 109- 1 16; Su et a!., 2009, Genes Dev 23(3):304-317).
  • Bim mRNA was initially assessed and found to be downregulated by about 80% in Bhd' ' ES cells compared to Bh ⁇ and Bhc ' ' cells, as depicted in Figure 7A.
  • Bhd' ' ES cells were treated with the proteasome inhibitor MG-132, but no increase in BimEL and BimL protein was observed, despite accumulation of ubiquitinated HIF- ⁇ ⁇ under the same treatment, as depicted in Figure 8A (Dehan et al. t 2009, Mol Cell 33(1): 109-1 16).
  • Bim expression is known to be regulated by Chop, a transcription factor activated by ER stress as part of the unfolded protein response (UPR) (Puthalakath et ai, 2007, Cell 129(7): 1337- 1349). Serum and amino acid withdrawal stimulate eIF2ct kinase activity through the nutrient-sensing GCN2 pathway, which also regulates Chop activity (Berlanga et «/., 1999, Eur J Biochem 265(2):754-762; Harding et al. t 2000, Mol Cell 6(5): 1099- 1 108).
  • Chop a transcription factor activated by ER stress as part of the unfolded protein response (UPR)
  • Serum and amino acid withdrawal stimulate eIF2ct kinase activity through the nutrient-sensing GCN2 pathway, which also regulates Chop activity (Berlanga et «/., 1999, Eur J Biochem 265(2):754-762; Harding
  • Example 5 Bhd 1" ES cells show many phenotypic and molecular defects characteristic of TGFB-pathwav mutants
  • TGF i Iigand as well as the receptors TGFpRl and TGFpRIl have been shown to be necessary for yolk sac vasculogenesis and normal embryonic hematopoiesis in vivo, and in ES cell-derived cystic embryo id body (EB) cultures, an in vitro model of yolk sac
  • Bh /+ and Bhd EBs were generated in methylcellulose cultures which promotes the differentiation of hematopoietic lineages. Bhd EBs failed to form
  • Bhd A ES cells exhibit molecular and developmental deficits related to yolk sac and hematopoietic differentiation that mimic those of TGFp Hgand and receptor mutants.
  • TGFp-mediated transcription is downreguiated due to hypo-acetylation of target gene promoters
  • Bhct ⁇ ES cells demonstrated a significant increase in relative levels of acetylated histone H3 at the Lefty 1 promoter after one hour of activin treatment, Bhd ES cells exhibited no response, as depicted in Figure 13C, This difference in acetyl-H3 at the Lefty I promoter was not due to a global reduction of acetyi-H3 levels, as these were unchanged by Western blot in i?fti/ + versus Bhd ES cells with and without activin, as depicted in Figure 13D.
  • Bhd A cells were treated with a low dose of the histone deacetylase (HDAC) inhibitor trichostatin A (TSA). It was observed that TSA treatment of Bhd A BS cells restored mRNA levels of several TOFp target genes, such as PAI- l,pl5 and Bim, to levels seen in Bfu + cells, as depicted in Figure 13E.
  • HDAC histone deacetylase
  • TSA treatment of Bhd A BS cells restored mRNA levels of several TOFp target genes, such as PAI- l,pl5 and Bim, to levels seen in Bfu + cells, as depicted in Figure 13E.
  • TSA treatment rescued the death resistance phenotype of Bhd ES cells in response to amino acid deprivation, as assessed by FACs analysis and depicted in Figure 6F (upper), and caspase and parp cleavage by Western blot along with a concomitant restoration of Bim protein expression (lower).
  • Treatment of ceils with TSA under non-starvation conditions did not induce cell death, eliminating the possibility that non-specific toxic effects of TSA mediated this effect (data not shown).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour le traitement de tumeurs basées sur le syndrome BHD chez un mammifère. Les procédés comprennent l'administration à un mammifère d'une quantité efficace d'un agent thérapeutique qui favorise ou induit une apoptose dépendante du TGF-β dans la tumeur basée sur le syndrome BHD. Les agents thérapeutiques de la présente invention comprennent des molécules BH3 seulement, des inhibiteurs de HDAC, des inhibiteurs d'autophagie et des vecteurs d'expression qui codent pour BHD, BIM et des composants de la voie de signalisation de TGF-β.
PCT/US2011/027507 2010-03-09 2011-03-08 Nouvelles approches thérapeutiques pour le syndrome de birt-hogg-dube (bhd) WO2011112554A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31192410P 2010-03-09 2010-03-09
US61/311,924 2010-03-09

Publications (1)

Publication Number Publication Date
WO2011112554A1 true WO2011112554A1 (fr) 2011-09-15

Family

ID=44563802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/027507 WO2011112554A1 (fr) 2010-03-09 2011-03-08 Nouvelles approches thérapeutiques pour le syndrome de birt-hogg-dube (bhd)

Country Status (1)

Country Link
WO (1) WO2011112554A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022165313A1 (fr) 2021-02-01 2022-08-04 Regenxbio Inc. Thérapie génique de céroïdes-lipofuscinoses neuronales

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AMMANAMANCHI ET AL.: "Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells", J BIOL CHEM., vol. 279, no. 31, 30 July 2004 (2004-07-30), pages 32620 - 32625 *
BELLODI ET AL.: "Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells", J CLIN INVEST., vol. 119, no. 5, May 2009 (2009-05-01), pages 1109 - 1123 *
CASH: "Molecular mechanisms of the Birt-Hogg-Dube tumor suppressor, dissertation", UNIVERSITY OF PENNSYLVANIA, 1 January 2010 (2010-01-01), Retrieved from the Internet <URL:http://repository.upenn.edu/dissertations/AAI3429199/> *
HONG ET AL.: "Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-Beta signaling", MOLECULAR CANCER, vol. 9, 2010, pages 160, XP021077899, DOI: doi:10.1186/1476-4598-9-160 *
HUDON ET AL.: "Renal tumour suppressor function of the Birt-Hogg-Dub? syndrome gene product folliculin", J MED GENET., vol. 47, no. 3, March 2010 (2010-03-01), pages 182 - 189 *
OLTERSDORF ET AL.: "An inhibitor of Bcl-2 family proteins induces regression of solid tumours", NATURE., vol. 435, no. 7042, 2 June 2005 (2005-06-02), pages 677 - 681, XP002491257, DOI: doi:10.1038/nature03579 *
WILDEY ET AL.: "Smad3 potentiates transforming growth factor beta (TGFbeta induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes", J BIOL CHEM., vol. 278, no. 20, 16 May 2003 (2003-05-16), pages 18069 - 18077 *
ZHANG J ET AL.: "Different gene expression profiles of AD293 and HEK293 cell lines that show contrasting susceptibility to apoptosis induced by overexpression of Bim L", ACTA BIOCHIM POL., vol. 53, no. 3, 2006, pages 525 - 530 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022165313A1 (fr) 2021-02-01 2022-08-04 Regenxbio Inc. Thérapie génique de céroïdes-lipofuscinoses neuronales

Similar Documents

Publication Publication Date Title
USRE49229E1 (en) Methods and compositions for treating malignant tumors associated with KRAS mutation
US9534219B2 (en) Methods of treating vascular inflammatory disorders
US20130266588A1 (en) Agents, Compositions, And Methods For Treating Pruritis And Related Skin Conditions
KR20160054595A (ko) 보체 인자 b의 조절자
US10792299B2 (en) Methods and compositions for treating malignant tumors associated with kras mutation
US11352628B2 (en) Methods and compositions for treating malignant tumors associated with KRAS mutation
EP3204014B1 (fr) Procédés de modulation des réponses du système immunitaire
WO2019126524A1 (fr) Cibles thérapeutiques pour un carcinome hépatocellulaire induit par une shna
JP6503289B2 (ja) 脂漏性角化症を治療および予防するための薬剤および方法
US9623109B2 (en) Methods of killing cells and use of same in prevention and treatment of cancer
KR20220012339A (ko) Alt 암 치료
WO2023055885A2 (fr) Inhibition de l&#39;ezh2 dans le cancer du pancréas
US20230383292A1 (en) Targeting xist and rna methylation for x reactivation therapy
WO2011112554A1 (fr) Nouvelles approches thérapeutiques pour le syndrome de birt-hogg-dube (bhd)
WO2016098873A1 (fr) Procédé pour déterminer le risque de développement d&#39;un lymphome primaire du système nerveux central et composition pour le traitement d&#39;un lymphome primaire du système nerveux central
US20230374505A1 (en) Human XIST Antisense Oligonucleotides for X Reactivation Therapy
US20210380988A1 (en) Reducing Prominin2-Mediated Resistance to Ferroptotic Cell Death
US20220275373A1 (en) Methods and compositions for treating malignant tumors associated with kras mutation
US20210324385A1 (en) Compositions and Methods for Treating Endometriosis
WO2010024405A1 (fr) Inhibiteur de la production de l&#39;ifn de type-1 et sa méthode de recherche
CA2680058C (fr) Induction d&#39;apoptose et inhibition de proliferation cellulaire par modulation de l&#39;activite carnitine palmitoyltransferase 1c
EP3956448A2 (fr) Inhibiteurs de aim2 et leurs utilisations
WO2018151840A2 (fr) Méthodes et compositions de traitement de tumeurs malignes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11753905

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11753905

Country of ref document: EP

Kind code of ref document: A1